Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pertussis syrup (also known as Bai-Ri-Ke syrup or BRK) is a traditional Chinese medicine (TCM) hospital preparation developed by Tianjin Second People's Hospital. It is formulated as an oral syrup containing multiple herbal ingredients, including bitter apricot seed, honey-fried loquat leaf, stemona root, trichosanthes fruit, and bamboo shavings. The syrup is primarily indicated for the treatment of pertussis (whooping cough) and other cough and asthma-related conditions in children, working by clearing the lungs, resolving phlegm, and relieving cough. Clinical and preclinical studies have also investigated its therapeutic effects on acute lung injury (ALI) and its impact on intestinal flora based on the TCM theory of the lung and large intestine being interior-exteriorly related.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pertussis syrup.